When Rituximab Stops Working: — Resistance and What Comes Next

It means the cancer progressed while you were receiving a rituximab-containing regimen, or came back within six months of finishing it. That six-month threshold is the clinical marker most guidelines use to define resistance, because it separates disease that was never controlled from disease that had a sustained response before returning. If you are unsure which category applies to you, ask your oncologist to explain it in plain terms.

If the relapse happens late — more than a year or two after stopping treatment — some oncologists will consider re-challenging with rituximab as part of a new regimen, depending on how long the original response lasted and what other treatment has been given since. This is not a standard recommendation for early or primary refractory disease, where a different approach is usually needed. Your oncologist will tell you whether it applies to your situation.

Both target CD20, but they bind to it differently and trigger cell death through different pathways. Obinutuzumab is a Type II anti-CD20 antibody, which means it induces a form of direct cell death more strongly than rituximab does, and it causes less of the CD20 'shaving' that can blunt rituximab's effect over time. NCCN and ESMO guidelines include it as an option in several relapsed B-cell lymphoma settings and in some CLL regimens where rituximab has already been used.

CAR-T therapy is approved for certain relapsed or refractory large B-cell lymphomas and some other blood cancers, and NCCN, ESMO, and ASCO guidelines include it in the treatment algorithm for eligible patients. It requires a specialist centre with the infrastructure to collect, process, and re-infuse the modified cells, and to manage the serious side effects that can follow. CION does not provide CAR-T therapy; if your oncologist considers you a candidate, they will refer you to a centre that does.

Most second-line chemotherapy regimens include a response assessment scan — usually a CT or PET-CT — after two to three cycles. For targeted agents, the timeline varies. What your oncologist is looking for is whether the disease is shrinking and by how much, because that response determines whether you proceed to the next step — which may be a transplant, further treatment, or a clinical trial. Ask your team when the first response assessment is planned and what they will be looking for.

Rituximab resistance means that particular approach is no longer working — it does not automatically determine how the cancer will respond to different treatments. Some patients who are refractory to rituximab-containing regimens respond well to second-line options. Your oncologist's goal at this point is to identify which approach is most likely to work based on your tumour's current biology, which is why re-testing at relapse is part of the process.